Not a good buy right now for an impatient trader: there’s no near-term catalyst, no proprietary buy signals, and the technical setup is not convincingly bullish.
Price is sitting just below the key pivot (~2.228) in pre-market (2.22); without a clean break above pivot/R1, upside follow-through looks limited.
With no news flow and weak/unstable fundamentals (no revenue; sharp YoY deterioration in net income/EPS), this is better treated as a watchlist name unless it shows a technical breakout.
Trend/Momentum: MACD histogram is above 0 (bullish bias) but positively contracting, implying fading upside momentum rather than acceleration.
RSI(6) ~44.5: neutral-to-soft; not oversold enough to suggest a strong bounce setup.
Moving averages: converging, consistent with consolidation/chop rather than a directional trend.
Key levels: Pivot 2.228 is immediate decision point.
Resistance: R1 2.393 then R2 2.494 (needs breakout to validate upside).
Support: S1 2.064 then S2 1.963 (loss of 2.064 would tilt the setup bearish).
Pattern-based projection (provided): modest edge higher (next day +0.35%, next week +0.96%, next month +4.86%), but not strong enough to override lack of signals/catalysts for an impatient entry.
Positive Catalysts
followed by a breakout over R1 (2.
could attract momentum buying.
Neutral/Negative Catalysts
No news in the last week: absence of event-driven catalysts reduces the odds of a fast, tradable move (important for an impatient strategy).
Momentum is weakening (MACD contracting) and RSI is below 50, which can lead to sideways-to-down chop.
Broader tape: S&P 500 pre-market is -0.6%, which can pressure small-cap/speculative names.
Fundamental profile remains fragile (no revenue; profitability metrics deteriorated sharply YoY).
Financial Performance
Latest reported quarter: 2025/Q3.
Revenue: 0 (no operating revenue base), YoY change shown as 0.00%.
Net income: 26,806, down -100.79% YoY (sharp deterioration).
EPS: 0.01, down -101.23% YoY.
Gross margin: 0, down -100.00% YoY.
Takeaway: financials do not show improving growth momentum; this increases reliance on external catalysts (trial updates, financings, partnerships), none of which are present in the provided news feed.
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
No analyst rating or price target change data was provided, so a clear “Wall Street” pro/con consensus can’t be confirmed from this dataset.
Practical read: limited/unclear street sponsorship typically means fewer catalyst-driven upgrades/downgrades to propel a fast move.
Politicians/congress: no recent congress trading data available in the last 90 days (no signal from that channel).
Wall Street analysts forecast KPRX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for KPRX is 12 USD with a low forecast of 12 USD and a high forecast of 12 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
Wall Street analysts forecast KPRX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for KPRX is 12 USD with a low forecast of 12 USD and a high forecast of 12 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 2.120
Low
12
Averages
12
High
12
Current: 2.120
Low
12
Averages
12
High
12
H.C. Wainwright
H.C. Wainwright
Buy
maintain
$10
AI Analysis
2025-07-22
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$10
AI Analysis
2025-07-22
maintain
Buy
Reason
H.C. Wainwright reiterates a Buy rating and $10 price target on shares of Kiora Pharmaceuticals after the company announced that it received received a U.S. patent covering KIO-104 for the treatment of ocular diseases, including ocular inflammation, uveitis, age-related macular degeneration, and complications from refractive surgery. The patent covers varying dosing schedules, necessary excipients, and other novel methods for optimizing treatment of ocular inflammatory diseases, the analyst tells investors in a research note. The new patent should strengthen the company's IP portfolio and help secure the potential market prospects if KIO-104 is successfully developed in clinical studies, the firm says.
